eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 15
Clinical research

Direct results of a prospective randomized study comparing ablation with the nMARQ catheter and the PVAC catheter used with and without a 3D system (MAPER 3D Study)

Edward Koźluk, Agnieszka Piątkowska, Dariusz Rodkiewicz, Michał Peller, Janusz Kochanowski, Grzegorz Opolski

Arch Med Sci 2019; 15, 1: 78–85
Online publish date: 2017/05/30
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Our aim was to compare in a prospective randomized study the safety, direct results and periprocedural data of ablation using an nMARQ catheter, a PVAC catheter used with the EnSite system, or a PVAC catheter only under fluoroscopy control.

Material and methods
One hundred two patients (70 male, 57 ±11 years) with atrial fibrillation (AF) were prospectively randomized to: group 1 – ablation performed with an nMARQ catheter and the CARTO 3 system; group 2 – a PVAC catheter used with the EnSite system; group 3 – ablation with a PVAC catheter without a 3D system.

Complete isolation of 400/402 pulmonary veins (PV) (99.5%). Linear ablation was performed in 23 patients in group 1 (small distance between lines isolating PV), in 3 patients in group 2, in 1 patient in group 3. The superior vena cava was isolated in 1 patient, 9 patients, and 9 patients respectively. Duration of fluoroscopy and dose area product were significantly smaller in group 1 (6.5 ±2.9 min/808.8 ±393.9 cGy/cm2 vs. 13.6 ±5.6 min/1662.6 ±677.8 cGy/cm2 and 18.8 ±7.6 min/2327.9 ±975.5 cGy/cm2; p < 0.001). Procedure duration was shorter in group 1 (82.9 ±18.8 min vs. 101.2 ±19.6 min, p < 0.001 and 99.8 ±20.8 min, NS). Contrast injection was necessary in 2 patients in group 1, in 8 patients in group 2 and in all patients in group 3. Because nMARQ is a thermocool catheter, the volume of fluid injection was significantly greater (2348.5 ±543.5 ml vs. 1077.9 ±280.5 ml and 1076.5 ±375.6 ml, p < 0.001). There were no periprocedural deaths. We observed no cardiac tamponade, neurological complications and no atrioesophageal fistula during follow-up.

The lowest radiological exposure was observed during ablation performed with an nMARQ catheter. 3D systems reduced fluoroscopy duration and the necessity of contrast injection. The nMARQ catheter requires injection of a large volume of fluid.


atrial fibrillation, radiofrequency catheter ablation, pulmonary vein isolation, PVAC catheter, nMARQ catheter

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609-78.
Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14: 528-606.
Kuck KH, Fürnkranz A, Chun KR, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J 2016; 37: 2858-65.
Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016; 374: 2235-45.
Neumann T, Vogt J, Schumacher B, et al. Circumferential pulmonary vein isolation with the cryoballoon technique results from a prospective 3-center study. J Am Coll Cardiol 2008; 52: 273-8.
Koźluk E, Gaj S, Piątkowska A, et al. Evaluation of safety and the success rate of cryoballoon ablation of the pulmonary vein ostia in patients with atrial fibrillation: a preliminary report. Kardiol Pol 2010; 68: 175-80.
Koźluk E, Balsam P, Peller M, et al. Efficacy of multi-electrode duty-cycled radiofrequency ablation in patients with paroxysmal and persistent atrial fibrillation. Cardiol J 2013; 20: 618-25.
Koźluk E, Piątkowska A, Kiliszek M, et al. Ablation of the atrial fibrillation substrate using 3D electroanatomical system and irrigated radiofrequency multipolar ablation catheter – preliminary report. Pol Przegl Kardiol 2014; 16: 69-74.
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-413.
Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-8.
McCready J, Chow AW, Lowe MD, et al. Safety and efficacy of multipolar pulmonary vein ablation catheter vs. irrigated radiofrequency ablation for paroxysmal atrial fibrillation: a randomized multicentre trial. Europace 2014; 16: 1145-53.
Lauschke J, Schneider R, Wissmann J, Tischer T, Bänsch D. Single-catheter approach to pulmonary vein reisolation in selected patients: data from a prospective registry. Herz 2016; 41: 625-9.
De Greef Y, Buysschaert I, Schwagten B, Stockman D, Tavernier R, Duytschaever M. Duty-cycled multi-electrode radiofrequency vs. conventional irrigated point-by-point radiofrequency ablation for recurrent atrial fibrillation: comparative 3-year data. Europace 2014; 16: 820-5.
Rosso R, Chorin E, Levi Y, Rogowski O, Viskin S. Radio­frequency ablation of atrial fibrillation: nonrandomized comparison of circular versus point-by-point “smart” ablation for achieving circumferential pulmonary vein isolation and curing arrhythmic symptoms. Cardiovasc Electrophysiol 2016; doi: 10.1111/jce.13058.
Laish-Farkash A, Khalameizer V, Fishman E, et al. Safety, efficacy, and clinical applicability of pulmonary vein isolation with circular multi-electrode ablation systems: PVAC® vs. nMARQ™ for atrial fibrillation ablation. Europace 2016; 18: 807-14.
Stec S, Sledź J, Mazij M, et al. Feasibility of implementation of a “simplified, No-X-Ray, no-lead apron, two-catheter approach” for ablation of supraventricular arrhythmias in children and adults. J Cardiovasc Electrophysiol 2014; 25: 866-74.
Koźluk E, Gawrysiak M, Piątkowska A, et al. Radiofrequency ablation without the use of fluoroscopy – in what kind of patients is it feasible? Arch Med Sci 2013; 9: 821-5.
Bulava A, Hanis J, Eisenberger M. Catheter ablation of atrial fibrillation using zero-fluoroscopy technique: a randomized trial. Pacing Clin Electrophysiol 2015; 38: 797-806.
Mühl A, Kühne M, Sticherling C, Knecht S. Fluoroscopy-free PVI with nMARQ(TM) in a patient with a PFO.
J Cardiovasc Electrophysiol 2015; 26: 906.
Vurma M, Dang L, Brunner-La Rocca HP, et al. Safety and efficacy of the nMARQ catheter for paroxysmal and persistent atrial fibrillation. Europace 2016; 18: 1164-9.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe